NAS10026,946−5.25%S&P7,428−3.39%GOLD$4,132+1.46%BTC$75,633−5.94%VIX23.84+43.53%latest tape · as of 18:03 UTC
The Screen · Consumer Defensive · Beverages - Non-Alcoholic
Monster Beverage
MNST · a US exchange · USD · Market cap $90.8B · 5,773 employees
Monster Beverage Corporation, through its subsidiaries, engages in development, marketing, sale, and distribution of energy drink beverages and concentrates in the United States and internationally.
Positioning political selling, disclosed 2026-09-11
Options put/call open interest 0.54, read 2026-11-05
Ethical passes the values gate
Price48.75 USD
Fair value38.07
Ethical score80.4/100
Value readOvervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-11-03Read Markup48.02+1.5% to today ✓Accumulation gives way to Markup after a 6% rise in 9 days
2026-10-25Read Accumulation45.34+7.5% to today ✓Markup gives way to Accumulation first Accumulation read since October
2026-10-18Read Markup45.34+7.5% to today ✓Accumulation gives way to Markup after a 5% rise in 7 days
2026-10-11Read Accumulation43.11+13.1% to today ✓Markdown gives way to Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Monster Beverage holds its Markup at $48.75. Consolidating, no directional conviction, held for 38 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 38 days
Price at the screen
$48.75
Valuation
42.92 trailing · 35.47 forward price to earnings
Values screen
PASS· score 80.4
Beta
0.49
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
17.37%
Below 33%
Interest-bearing debt is just 17.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.88%
Below 33%
Cash held in interest-bearing accounts and securities is 4.9% of assets, under the one-third limit.
Pass
Receivables
37.10%
Below 49%
Money owed to the company is 37.1% of assets, under the 49% limit.
Pass
Revenue purity
0.76%
Below 5%
Only 0.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Monster Beverage clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 17%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MNST's ethical verdict changes
Today MNST passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 4 Nov 2026: it trades above our $38.07 fair value estimate, strong competitive moat, 20.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 28.1% above the base estimate.
Where our models see it going: fair-value estimate $38.07, with a range of $31.50 to $43.78, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Energy cans stack up but the price tag does not
Walk into any corner shop at midnight and the fridge glows with Monster cans. The brand has built a genuine moat in energy drinks, with revenue up 27 percent, a 23 percent profit margin and 27 percent ROE. Those numbers explain why the business clears our ethical screen with ease.
Yet the shares sit at 97.50 dollars against our fair value of 73.43 dollars, a 25 percent premium. A forward multiple of 37.6 times leaves no room for the growth to slow even a notch, and analyst targets cluster around 95 dollars. This is a case of paying up for quality that already looks fully priced.
The real risk is simple: if volume growth moderates or competition intensifies, the multiple can compress quickly. High returns on capital are already reflected in the quote, so any disappointment lands straight on the share price. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MNST trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$48.75+3.3%Entry 24
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markup$47.18-1.7%Entry 23
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup · changed$48.02+1.4%Entry 22
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$47.34+0.0%Entry 21
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$47.34+0.0%Entry 20
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$47.34+2.1%Entry 19
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$46.35+1.5%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$45.66+0.7%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89.
2026-10-18Markup · changed$45.34+5.2%Entry 15
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it buy, with a mean price target of $89.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
